How to improve the Customer Experience in Telecoms with Tech

Improving the support, experience and success of customers is the ultimate service goal for any industry or organization, and it is especially critical in telecom. Jay Anderson, CTO, Fiberlight, knows how essential all three are to the overall success of both his customers and his company.

He joined Cleide Lund, Director of Product Services at 3-GIS, and host Tyler Kern for a customer-centric Fiberside Chat.

“In our business, most of our customers are larger enterprise customers, as well as other content providers and other large carriers, themselves,” Anderson said. “And, so, having rapid access in our environment when it comes to infrastructure, internet access, as well as just transport for data services is hugely instrumental in the businesses that are buying our services. Having quick access to that means a happy customer.”

“Customer experience is everything for a company,” Lund added. “It includes a lot of moving pieces that boil down to the perception that the customer builds of our brand. So, for us, customer experience and customer success are of utmost importance. And for clients like Fiberlight, we want to feel that they know we are here to support them and proactively guide them on how to reach the expected outcomes better.”

The telecom industry moves rapidly, with constant changes in the marketplace and new requirements for different information. Customers rely on the CX systems of Fiberlight and 3-GIS to keep on top of these changes to deliver results.

“One hundred percent of our clients use our ticketing system to track all those inquiries or any tasks that they need to be done,” Lund said. “And, for us, it is very important to have one source of truth to provide that information to our clients, whether the ticket has been solved or is waiting on some resolution from the product side. Having the clients using that and having everyone have access to that makes the communication between our clients and us much more effective.”

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More